Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal closure. Analyst firm Needham downgraded Personalis from Buy to Hold, citing limited potential gains. The stock's future now depends on the successful completion of the acquisition by Tempus AI.
Julie & Holleman LLP is investigating whether Personalis shareholders are receiving fair value in Tempus AI's proposed acquisition at $16.25 per share. Tempus, already a significant shareholder and strategic partner since 2023, may have conflicts of ...
Tempus AI will acquire Personalis in a $1.5 billion all-stock deal, expanding its cancer recurrence monitoring capabilities. Personalis shareholders will receive $16.25 per share, a premium of 6% over the recent closing price. The acquisition builds ...
